Psychiatric clearance for patients started on interferon-alpha-based therapies

American Journal of Psychiatry

Volumn 170, Issue 6, 2013, Pages 592-597

  Lotrich, Francis E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BOCEPREVIR; CANNABIS; CITALOPRAM; CLONAZEPAM; CYTOCHROME P450 3A4; DULOXETINE; HEMOGLOBIN; IBUPROFEN; IRON; METFORMIN; MULTIVITAMIN; NEFAZODONE; PEGINTERFERON ALPHA; PEGYLATED INTERFERON ALPHA2A; PSYCHEDELIC AGENT; RECOMBINANT ALPHA INTERFERON A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; ALPHA INTERFERON;

ANHEDONIA; ANXIETY; ARTICLE; CARPAL TUNNEL SYNDROME; CRYING; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRINKING BEHAVIOR; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; ERYTHROCYTE TRANSFUSION; FATIGUE; FATTY LIVER; GUILT; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TOXICITY; MALAISE; MANIA; MENTAL DISEASE; METASTATIC MELANOMA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MOTIVATION; NAUSEA; PANCYTOPENIA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC CLEARANCE; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; RELAPSE; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; PSYCHOLOGICAL ASPECT;

ANTIVIRAL AGENTS; DEPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 84882252475     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12121572     Document Type: Article

References (66)

1. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91: 31-37
2. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ: Treatment of cytokine-induced depression. Brain Behav Immun 2002; 16: 575-580
3. Donnelly S: Patient management strategies for interferon alfa- 2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998; 25: 921-927
4. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L: Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-97
5. Trask PC, Esper P, Riba M, Redman B: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 2316-2326
6. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenback H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T: Escitalopram for the prevention of peginterferon-alpha-2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157: 94-103
7. Lotrich FE: Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009; 11: 417-425
8. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241-243
9. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM: Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-1211
10. Castéra L, Constant A, Henry C, Couzigou P: [Psychiatric disorders during treatment of chronic hepatitis C]. Gastroenterol Clin Biol 2005; 29: 123-133 (French)
11. Castera L, Constant A, Henry C, Champbenoit P, Bernard PH, De Ledinghen V, Demotes-Mainard J, Couzigou P: Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1223-1230
12. Dinwiddie SH, Shicker L, Newman T: Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160: 172-174
13. Batista-Neves SC, Quarantini LC, de Almeida AG, Bressan RA, Lacerda AL, de-Oliveira IR, Paraná R, Miranda-Scippa A: High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry 2008; 30: 80-82
14. Dan AA, Crone C, Wise TN, Martin LM, Ramsey L, Magee S, Sjogren R, Ong JP, Younossi ZM: Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 2007; 48: 223-229
15. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE: Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferonalpha treatment. Psychiatry Res 2010; 177: 240-245
16. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG: Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007; 63: 131-135
17. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG: Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol 2010; 33: 191-197
18. Kraus MR, Schäfer A, Schöttker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-536
19. Sockalingam S, Abbey SE: Managing depression during hepatitis C treatment. Can J Psychiatry 2009; 54: 614-625
20. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG: Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics 2004; 45: 29-33
21. Nickel T, Sonntag A, Backmund M, Pollmächer T: Depression during therapy with interferon alpha: how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: 102-104
22. Capuron L, Miller AH: Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004; 56: 819-824
23. Martin KA, Krahn LE, Balan V, Rosati MJ: Modafinil's use in combating interferon-induced fatigue. Dig Dis Sci 2007; 52: 893-896
24. Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29:E85-E90
25. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG: Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89: 356-362
26. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ: Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004; 161: 429-435
27. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47
28. Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller MB, Condemarín JR, Chiu N-M, Jacobson JM: Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003; 44: 417-420
29. Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-2 and interferonalpha treatments in cancer patients. Psychosom Med 2001; 63: 376-386
30. Malek-Ahmadi P, Hilsabeck RC: Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry 2007; 19: 113-123
31. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH: Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-1174
32. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE: Cytokineinduced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009; 23: 1109-1116
33. Lotrich FE, Sears B, McNamara RK: Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleukin-6. Brain Behav Immun (Epub ahead of print, Aug 19, 2012)
34. Nicklas BJ, Hsu F-C, Brinkley TJ, Church T, Goodpaster BH, Kritchevsky SB, Pahor M: Exercise training and plasma Creactive protein and interleukin-6 in elderly people. J Am Geriatr Soc 2008; 56: 2045-2052
35. Lambert CP, Wright NR, Finck BN, Villareal DT: Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol 2008; 105: 473-478
36. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, Miyazaki C, Alexander N, Hotopf M, Cleare AJ, Norris S, Cassidy E, Aitchison KJ, Miller AH, Pariante CM: Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009; 14: 1095-1104
37. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-123
38. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG: Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009; 65: 344-348
39. Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch KP, Scheurlen M: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007; 132: 1279-1286
40. Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC, Aitchison KJ, Pariante CM: Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated faty acids levels. Biol Psychiatry 2010; 67: 550-557
41. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH: Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342-1345
42. Lotrich FE, Albusaysi S, Ferrell RE: Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology (Epub ahead of print, Dec 18, 2012)
43. Felger JC, Alagbe O, Pace TWW, Woolwine BJ, Hu F, Raison CL, Miller AH: Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun 2011; 25: 1094-1098
44. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, Bauer J, Lieb K: Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383-389
45. Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Nemeroff CB, Berns GS, Miller AH: Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005; 58: 190-196
46. Capuron L, Pagnoni G, Demetrashvili MF, Lawson DH, Fornwalt FB, Woolwine B, Berns GS, Nemeroff CB, Miller AH: Basal ganglia hypermetabolism and symptoms of fatigue during interferonalpha therapy. Neuropsychopharmacology 2007; 32: 2384- 2392
47. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R: Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348-351
48. Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T: Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999; 24: 359-363
49. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH: Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906-914
50. Dunn AL, Crnic LS: Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun 1993; 7: 104-111
51. Wichers MC, Maes M: The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29: 11-17
52. Liu Y, Samuel CE: Editing of glutamate receptor subunit B premRNA by splice-site variants of interferon-inducible doublestranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 1999; 274: 5070-5077
53. Koyanagi S, Ohdo S: Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol Pharmacol 2002; 62: 1393-1399
54. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E: Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96: 157-164
55. Goldsmith J, Hauser P: Psychiatric issues in patients with hepatitis C. Psychiatr Ann 2003; 33: 357-360
56. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD: Hepatitis C treatment for people with severe mental illness. Psychosomatics 2006; 47: 93-107
57. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54: 565-572
58. Asnis GM, De La Garza RI 2nd: Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40: 322-335
59. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 433-451
60. Le Lan C, Guillygomarc'h A, Danielou H, Le Dréau G, Lainé F, Védeilhié C, Deugnier Y, Brissot P, Guyader D, Moirand R: A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol 2012; 56: 334-340
61. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T; VA-HCV-001 Study Group: Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-1616
62. Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, Cifuentes C, García-Rey S, Merchante N, Almeida C, Macías J, Pineda JA: Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis 2012; 31: 1225-1232
63. Reichenberg A, Gorman JM, Dieterich DT: Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19(suppl 3):S174-S178
64. Dieperink E, Ho SB, Thuras P, Willenbring ML: A prospective study of neuropsychiatric symptoms associated with interferonalpha- 2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-112
65. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-947
66. SchaeferM, Schmidt F, HornM, Schmid-WendtnerM-H,Volkenandt M: Depression during treatment with interferon alpha. Psychosomatics 2004; 45: 176